Amar­na rais­es €10M to push gene ther­a­py plat­form in­to clin­ic; Ed­i­tas Med­i­cine, AskBio join forces

→ Amar­na Ther­a­peu­tics  — de­vel­op­ing an SV40-based gene de­liv­ery vec­tor plat­form called SVac — has raised €10 mil­lion. The round was led by Swedish in­vest­ment com­pa­ny Flerie In­vest AB, along with con­tri­bu­tions from the Nether­lands En­ter­prise Agency and ex­ist­ing share­hold­er Pim Berg­er. The funds will be used to de­vel­op SVac and steer it in­to a first-in-man clin­i­cal study, ex­pect­ed to com­mence in the com­ing years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER